Neutrophils, which are the most abundant circulating leukocytes in humans, are the first line
of defense against bacterial and fungal infections. Recent studies have reported the role and …

Despite considerable amount of research, the poor prognosis of patients diagnosed with
glioblastoma multiforme (GBM) critically needs new drug development to improve clinical …

Implantation of biodegradable wafers near the brain surgery site to deliver anti-cancer
agents which target residual tumor cells by bypassing the blood-brain barrier has been a …

Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to
upregulation of O 6-methylguanine-DNA methyltransferase (MGMT). Wild-type (wt) p53 was …

Abstract Development of temozolomide (TMZ) resistance contributes to the poor prognosis
for glioblastoma multiforme (GBM) patients. It was previously demonstrated that delivery of …

One of the hallmark features of glioblastoma multiforme (GBM), the most common adult
primary brain tumor with a very dismal prognosis, is the accumulation of CD4+ CD25+ …

Although temozolomide (TMZ) is the current first-line chemotherapy for glioblastoma
multiforme (GBM), most patients either do not respond or ultimately fail TMZ treatment. Both …

Background Glioblastoma (GBM) is a poorly immunogenic neoplasm treated with focused
radiation. Immunotherapy has demonstrated synergistic survival effects with stereotactic …

Glioblastoma multiforme is a highly aggressive primary cancer of the brain associated with a
poor prognosis. Modest increases in survival can sometimes be achieved with the use of …

The current standard of care for glioblastoma (GBM) is maximal surgical resection with
adjuvant radiotherapy and temozolomide (TMZ). As the 5-year survival with GBM remains at …